- Title:
SP Angel Research Note - Time:
09:15:03 - Date:
18 Nov 2020 - Category:
Miscellaneous - ID:
7079F
18 November 2020
N4 Pharma plc
("N4 Pharma" or the "Company")
SP Angel Research Note
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce that its joint broker SP Angel Corporate Finance LLP has issued an initiation research report on the Company.
To view SP Angel's research note, please visit the Company's website:
https://www.n4pharma.com/investors/investor-information/
Enquiries:
| N4 Pharma plc |
|
| Nigel Theobald, CEO |
Via IFC Advisory |
| Luke Cairns, Executive Director |
|
| |
|
| SP Angel Corporate Finance LLP |
Tel: +44(0)20 3470 0470 |
| Nominated Adviser and Joint Broker |
|
| Matthew Johnson/Caroline Rowe (Corporate Finance) |
|
| Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) |
|
| |
|
| Turner Pope Investments (TPI) Limited |
Tel: +44(0)20 3657 0050 |
| Joint Broker |
|
| Andy Thacker |
|
| |
|
| IFC Advisory Ltd Financial PR Graham Herring Zach Cohen |
Tel: +44(0)20 3934 6630 |
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.
N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre-clinical and clinical programmes, N4 Pharma will seek to receive up-front payments, milestone payments and ultimately royalty payments once products reach the market.
SP Angel Research Note09:15:0318 Nov 2020Miscellaneous7079F